Neurology Department, Cluj Emergency County Hospital, 400012 Cluj-Napoca, Romania; Department of Neurosciences, Faculty of Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, Iuliu Haţieganu University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
J Neuroimmunol. 2023 May 15;378:578087. doi: 10.1016/j.jneuroim.2023.578087. Epub 2023 Apr 7.
Gut microbiota, the total microorganisms in our gastrointestinal tract, might have an implication in multiple sclerosis (MS), a demyelinating neurological disease. Our study included 50 MS patients and 21 healthy controls (HC). Twenty patients received a disease modifying therapy (DMT), interferon beta1a or teriflunomide, 19 DMT combined with homeopathy and 11 patients accepted only homeopathy. We collected in total 142 gut samples, two for each individual: at the study enrolment and eight weeks after treatment. We compared MS patients' microbiome with HC, we analysed its evolution in time and the effect of interferon beta1a, teriflunomide and homeopathy. There was no difference in alpha diversity, only two beta diversity results related to homeopathy. Compared to HC, untreated MS patients had a decrease of Actinobacteria, Bifidobacterium, Faecalibacterium prauznitzii and increased Prevotella stercorea, while treated patients presented lowered Ruminococcus and Clostridium. Compared to the initial sample, treated MS patients had a decrease of Lachnospiraceae and Ruminococcus and an increased Enterococcus faecalis. Eubacterium oxidoreducens was reduced after homeopathic treatment. The study revealed that MS patients may present dysbiosis. Treatment with interferon beta1a, teriflunomide or homeopathy implied several taxonomic changes. DMTs and homeopathy might influence the gut microbiota.
肠道微生物群，即我们胃肠道中的总微生物群，可能与多发性硬化症（MS）有关，多发性硬化症是一种脱髓鞘神经系统疾病。我们的研究包括 50 名 MS 患者和 21 名健康对照（HC）。20 名患者接受了疾病修正治疗（DMT），即干扰素 beta1a 或特立氟胺，19 名患者接受了 DMT 联合顺势疗法，11 名患者仅接受了顺势疗法。我们共收集了 142 个肠道样本，每个个体采集两个样本：在研究入组时和治疗后 8 周。我们将 MS 患者的微生物组与 HC 进行了比较，分析了其随时间的演变以及干扰素 beta1a、特立氟胺和顺势疗法的影响。α多样性没有差异，只有两个与顺势疗法相关的β多样性结果。与 HC 相比，未经治疗的 MS 患者的放线菌、双歧杆菌、粪肠球菌减少，而普雷沃氏菌增多，而治疗患者的瘤胃菌和梭菌减少。与初始样本相比，治疗后的 MS 患者lachnospiraceae 和瘤胃菌减少，而粪肠球菌增加。经顺势疗法治疗后，Eubacterium oxidoreducens 减少。该研究表明，MS 患者可能存在肠道菌群失调。用干扰素 beta1a、特立氟胺或顺势疗法治疗会导致一些分类群的变化。DMT 和顺势疗法可能会影响肠道微生物群。
